1. Home
  2. NKTR vs JCE Comparison

NKTR vs JCE Comparison

Compare NKTR & JCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NKTR
  • JCE
  • Stock Information
  • Founded
  • NKTR 1990
  • JCE 2007
  • Country
  • NKTR United States
  • JCE United States
  • Employees
  • NKTR N/A
  • JCE N/A
  • Industry
  • NKTR Biotechnology: Pharmaceutical Preparations
  • JCE Trusts Except Educational Religious and Charitable
  • Sector
  • NKTR Health Care
  • JCE Finance
  • Exchange
  • NKTR Nasdaq
  • JCE Nasdaq
  • Market Cap
  • NKTR 247.9M
  • JCE 249.7M
  • IPO Year
  • NKTR 1994
  • JCE N/A
  • Fundamental
  • Price
  • NKTR $0.93
  • JCE $15.40
  • Analyst Decision
  • NKTR Buy
  • JCE
  • Analyst Count
  • NKTR 3
  • JCE 0
  • Target Price
  • NKTR $4.00
  • JCE N/A
  • AVG Volume (30 Days)
  • NKTR 2.3M
  • JCE 49.7K
  • Earning Date
  • NKTR 11-07-2024
  • JCE 01-01-0001
  • Dividend Yield
  • NKTR N/A
  • JCE 9.26%
  • EPS Growth
  • NKTR N/A
  • JCE N/A
  • EPS
  • NKTR N/A
  • JCE N/A
  • Revenue
  • NKTR $93,137,000.00
  • JCE N/A
  • Revenue This Year
  • NKTR $12.85
  • JCE N/A
  • Revenue Next Year
  • NKTR N/A
  • JCE N/A
  • P/E Ratio
  • NKTR N/A
  • JCE N/A
  • Revenue Growth
  • NKTR 5.53
  • JCE N/A
  • 52 Week Low
  • NKTR $0.47
  • JCE $11.64
  • 52 Week High
  • NKTR $1.93
  • JCE $14.28
  • Technical
  • Relative Strength Index (RSI)
  • NKTR 33.04
  • JCE 32.12
  • Support Level
  • NKTR $0.89
  • JCE $15.27
  • Resistance Level
  • NKTR $1.04
  • JCE $16.28
  • Average True Range (ATR)
  • NKTR 0.07
  • JCE 0.30
  • MACD
  • NKTR -0.00
  • JCE -0.10
  • Stochastic Oscillator
  • NKTR 14.81
  • JCE 0.00

About NKTR Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest

Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities (the Options Strategy).

Share on Social Networks: